Banque Transatlantique SA Acquires Shares of 15,468 TG Therapeutics, Inc. $TGTX

Key Points

• Banque Transatlantique SA has invested approximately $610,000 in TG Therapeutics, acquiring 15,468 shares during the first quarter.
• Analysts have set a new price target of $37.00 for TG Therapeutics, with an average rating of "Moderate Buy" and an average price target of $46.25.
• TG Therapeutics reported a 92.1% increase in quarterly revenue year-over-year, reaching $141.15 million, although it missed the EPS consensus estimate.

Banque Transatlantique SA bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 15,468 shares of the biopharmaceutical company's stock, valued at approximately $610,000.

A number of other institutional investors have also added to or reduced their stakes in TGTX. CWM LLC lifted its stake in shares of TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 290 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 433 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 26.8% in the first quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 511 shares in the last quarter. Xponance Inc. lifted its position in shares of TG Therapeutics by 5.3% during the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after buying an additional 543 shares during the last quarter. Finally, Choreo LLC boosted its holdings in shares of TG Therapeutics by 7.6% in the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after buying an additional 602 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Activity

In related news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director owned 228,816 shares of the company's stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.64% of the stock is currently owned by insiders.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded down $0.78 during midday trading on Tuesday, hitting $31.60. The company had a trading volume of 789,233 shares, compared to its average volume of 2,469,331. The company has a fifty day simple moving average of $32.74 and a 200 day simple moving average of $35.63. The stock has a market cap of $5.01 billion, a price-to-earnings ratio of 85.30 and a beta of 1.88. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12-month low of $21.16 and a 12-month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million for the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.